Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
                
Learn More
Learn More
                                    Layilin Antibody (328024), Janelia Fluor™ 549, Novus Biologicals™
 
                                    
                                    
                                    
                                    
                                
                            
                            
                            
                            
Mouse Monoclonal Antibody
Supplier: Novus Biologicals FAB2637I
                        
                            
                        
                        
                        
                            
                        
                        
                        
                        
                            
                                    
                                This item is not returnable.
                                View return policy
                                
                        
                    
                Description
Layilin Monoclonal antibody specifically detects Layilin in Human, Mouse samples. It is validated for Western Blot, Flow CytometrySpecifications
| Layilin | |
| Monoclonal | |
| Janelia Fluor 549 | |
| FLJ30977, FLJ31092, layilin | |
| Mouse myeloma cell line NS0-derived recombinant human Layilin, Ala22-Glu220, Accession # NP_849156 | |
| 0.1 mL | |
| Signal Transduction | |
| 143903 | |
| Store at 4°C in the dark. | |
| IgG1 | 
| Western Blot, Flow Cytometry | |
| 328024 | |
| 50mM Sodium Borate | |
| Mouse | |
| Protein A or G purified from hybridoma culture supernatant | |
| RUO | |
| Primary | |
| Human, Mouse | |
| Purified | 
                    Product Content Correction
                
                Your input is important to us. Please complete this form to provide feedback related to the content on this product.
Product Title
			
            Spot an opportunity for improvement?Share a Content Correction
            